Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Harnett

Showing results (41-50 of 70) with videos related to

Pageof 7
Sort By:
Gynecologic Oncology|October 11, 2005
MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinomaAlexander D Guminski, Rosemary L Balleine, Yoke-Eng Chiew, et al.
Cancers|July 2, 2021
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study ResultsJermaine I Coward, Minal A Barve, Ganessan Kichenadasse, et al.
Gynecologic Oncology|May 30, 2018
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistanceKristina Lindemann, Bo Gao, Cristina Mapagu, et al.
Gynecologic Oncology|June 1, 1988
Cisplatin plus VP 16-213 in advanced ovarian carcinomaP R Harnett, D R Bell, B L Hillcoat, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2013
Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 monthsPaul W Stoodley, David A B Richards, Anita Boyd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapySharon E Johnatty, Jonathan Beesley, Jim Paul, et al.
Gynecologic Oncology|July 23, 2016
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcomeBo Gao, Kristina Lindemann, Lyndal Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancerLyndee L Scurr, Alexander D Guminski, Yoke-Eng Chiew, et al.
Plos One|March 23, 2011
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesisCatherine Emmanuel, Natalie Gava, Catherine Kennedy, et al.
Translational Oncology|February 22, 2023
Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinomaOmali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, et al.
Pageof 7

Showing results (41-50 of 70) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|October 11, 2005
MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinomaAlexander D Guminski, Rosemary L Balleine, Yoke-Eng Chiew, et al.
Cancers|July 2, 2021
Maximum Tolerated Dose and Anti-Tumor Activity of Intraperitoneal Cantrixil (TRX-E-002-1) in Patients with Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer: Phase I Study ResultsJermaine I Coward, Minal A Barve, Ganessan Kichenadasse, et al.
Gynecologic Oncology|May 30, 2018
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistanceKristina Lindemann, Bo Gao, Cristina Mapagu, et al.
Gynecologic Oncology|June 1, 1988
Cisplatin plus VP 16-213 in advanced ovarian carcinomaP R Harnett, D R Bell, B L Hillcoat, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2013
Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 monthsPaul W Stoodley, David A B Richards, Anita Boyd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapySharon E Johnatty, Jonathan Beesley, Jim Paul, et al.
Gynecologic Oncology|July 23, 2016
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcomeBo Gao, Kristina Lindemann, Lyndal Anderson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancerLyndee L Scurr, Alexander D Guminski, Yoke-Eng Chiew, et al.
Plos One|March 23, 2011
Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesisCatherine Emmanuel, Natalie Gava, Catherine Kennedy, et al.
Translational Oncology|February 22, 2023
Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinomaOmali Pitiyarachchi, Yeh Chen Lee, Hao-Wen Sim, et al.
Pageof 7